Showing results (61-70 of 91) with videos related to
Sort By:
Pageof 10
The Journal of Clinical Investigation|March 5, 2013
IgG4 subclass antibodies impair antitumor immunity in melanomaPanagiotis Karagiannis, Amy E Gilbert, Debra H Josephs, et al.European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancerIan Chau, Andrew R Norman, David Cunningham, et al.British Journal of Haematology|March 22, 2003
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphomaIan Chau, Mark Harries, David Cunningham, et al.European Journal of Immunology|January 15, 2021
Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of actionZena N Willsmore, Ben G T Coumbe, Silvia Crescioli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2025
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES StudyGianmarco Leone, Yien Ning Sophia Wong, Robert J Jones, et al.Nature Communications|April 10, 2025
Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interactionGabriel Osborn, Jacobo López-Abente, Rebecca Adams, et al.Frontiers in Immunology|April 4, 2019
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in MelanomaDuaa O Khair, Heather J Bax, Silvia Mele, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2018
Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast CancerAnthony Cheung, James Opzoomer, Kristina M Ilieva, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinomaAndrew X Zhu, Olivier Rosmorduc, T R Jeffry Evans, et al.Allergy|February 13, 2022
AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position PaperChristoph Bergmann, Aurélie Poli, Ioana Agache, et al.Pageof 10